“OGT expands range of CytoCell IVDR-certified FISH probes for hematological malignancies”

Key points

• OGT launches four IVDR-certified CytoCell FISH probes for hematological malignancies.
• Probes target translocations involving IGH or ATM for disease characterization.
• Labs move from IVDD CE-marking to IVDR ahead of December 2028 deadline.
• Probes support NHL, ALL, CLL, and multiple myeloma workflows with reliable results.
• OGT provides on-site and digital support to validate and implement probes.